264
Participants
Start Date
June 30, 2006
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
lanreotide (Autogel formulation)
120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Placebo
Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Memorial Sloan-Kettering Cancer Center, New York
CHU la Timone, Marseille
Hôpital Rangueil, Toulouse
Hôpital R. Debré, Reims
University of Iowa, Iowa City
CAC Oscar Lambret, Lille
Hôpital Edouard Herriot, Lyon
CHI Frejus St Raphael, Saint-Raphaël
Cedars-Sinai Outpatient Cancer Center, Los Angeles
Hôpital A. Paré, Boulogne-Billancourt
Hôpital Beaujon, Clichy
Unité de gastro enterologie IGR, Villejuif
Providence Portland Medical Center, Portland
The John Hopkins Hospital, Baltimore
Dana Farber Cancer Institute, Boston
MD Anderson Cancer Center, Houston
University of Wisconsin School of Medicine and Public Health, Madison
University Hospital, Vienna
UZ Antwerpen, Antwerp
UCL Saint Luc, Brussels
UZ Gent, Ghent
Fakultni nemocnice Na, Bulovce
Fekultni nemocnice Olomouc, Olomouc
General faculty, Prague
Sygehus Hospital, Aarhus
Rigshospitalet, Copenhagen
Charite Hospital, Berlin
University Hospital, Erlangen
University Hospital, Lübeck
Gutenberg University Hospital, Mainz
University Hospital, München
Lukas Hospital, Neuss
Global Hospital, Hyderabad
Tata Memorial Hospital, Mumbai
Centro di Refierimiento Oncologica, Aviano
Azienda Malpighi, Bologna
INSCT, Milan
University of Naples, Naples
Hospital S. Chiara, Pisa
Azienda San Giovanni Battista, Torino
UMC Gronigen, Gronigen
Erasmu MC, Rotterdam
UMC Utrecht, Utrecht
Centrum Onkologii-Instytut im. Marii Sklodowskiej - Curie, oddzial w Gliwicach, Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej ul., Gliwice
Katedra i Klinika Endokrynologii Przemiany Materii i Chorob Wewnetrznych Uniwersytetu Medycznego w Poznaniu, Poznan
Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika Chorob Wewnetrznych I Endokrynologii ul. Banacha 1 a, Warsaw
Szpital Bielanski im. Ks. Jerzego Popieluszki, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Endokrynologii Centrum Medycznego Ksztalcenia Podyplomowego, Warsaw
Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Ministrerstwa Spraw Wewnetrznych i Administratracji w Warzawie, Warsaw
Silesian Medical University, Zabrze
Narodny onkologicky ustav, Bratislava, Slovakia
Vychodoslovensky onkologicky ustav, Rastislavova, Slovakia
Hospital Vall d'Hebron, Barcelona
Institut Catala Oncologia, Barcelona
Hospital G. Maranon, Madrid
Hospital La Paz, Madrid
Hospital Nuestra Senora de la Candelaria, Santa Cruz de Tenerife
Sahlgrenska Hospital, Gothenburg
Karolinska University Hospital, Stockholm
University Hospital, Uppsala
Basingstoke and North Hampshire Hospital, Basingstoke
Royal Victoria Hospital, Belfast
University Hospital Wales, Cardiff
Western General Hospital, Edinburgh
Beatson West of Scotland Cancer Centre, Glasgow
St James Hospital, Leeds
Leicester Royal Infirmary, Leicester
Royal Free Hospital, London
St Bartholomew's Hospital, London
QMC, Nottingham
Churchill Hospital, Oxford
Royal Hallamshire Hospital, Sheffield
Lead Sponsor
Ipsen
INDUSTRY